respond to this post

 
Here is the link to the screencast
https://screencast-o-matic.com/watch/cF1VeXbLLg (Links to an external site.)Links to an external site.
Also attached is my full powerpoint presentation.
Here is my transcript, starting at slide three because the first two slides are a title slide and the table of contents.
Slide 3 
Hello. My name is Kathy Rundell.  Today I will be giving a generally technical understanding of depression.  Specifically, this presentation will address classic and current theories of the mechanics of depression as well as several aspects of typical and futuristic treatment. 
Slide 4 
There are several varieties of depression ranging in severity which affect around 300 million people on the planet according to McLean (2018).  Most commonly general depression is treated with anti-depressants such as Prozac and therapy/counseling.  For some symptoms go away and they are eventually able to stop taking the medication.  General depression can become chronic when it either goes and comes in waves or does not go away for long periods of time.  An affective disorder, depression, or major depression disorder (MDD) can impact every aspect of who one is from mood, to interests, to self-worth and value. 
Slide 5 
It has been thought that MDD is a result of an imbalance of several specific chemicals and neurotransmitters in the brain.  Particularly serotonin, norepinephrine, and dopamine seem to be related.  The medicine chosen for treatment would carry the specific function of aiding in the regulation of these substances.  Tackman et. Al. (2018) discuss reports of more generalized depression after something important in one’s life becoming associated with a negative outcome. 
Slide 6 
New research avenues have led to several innovations to theories and treatments.  Advokat et. Al. (2014) talks about the neurogenic theory of depression.  They explain that neurogenesis (when new neurons are made) allows for areas related to depressive disorders such as the frontal cortex and hippocampus to repair damage and pathways for neurons to travel.  EDD is known to occur comorbidly and one disorder very common is generalized anxiety disorder (GAD).  A study done by Mennin et. Al. (2018) says that emotion regulation therapy had a largely positive effect on 83% of both the GAD and MDD individually for the patients. 
Slide 7 
By far typical treatment for MDD is anti-depressants designed to aid in fixing and protecting at the cellular level.  It seems as though stress, whether chronic life stress, or stress from injury to specific areas has a direct line to the development of depression.  Discoveries like these have been linked with high relapse rates and only about 50% success with anti-depressants have led to new treatment research into more herbal medicines.  Specifically, McLean (2018) mentions an herb called crocus sativus (saffron) due to antioxidant, anti-inflammatory and neuroprotective properties. 
Slide 8 
As with any medication there is risk for side effects.  In this case the term is treatment-resistant depression and refers to effects such as weight gain, memory lapse, and even suicidal ideation (Advokat et. Al., 2014).  This tends to happen more in those with less severe symptoms.  Anti-depressants are hugely beneficial in more severe cases and in comorbid treatment plans though.  Specified therapies can also have a great and positive effect on sufferers as pointed out by McLean (2018) and Mennin et. Al. (2018).  With no treatment at all symptoms are sure to escalate, not diminish, over time.  Sometimes even with treatment, but typically without, suicide becomes the biggest risk. 

Advokat, C. D., Comaty, J. E., & Julien, R. M. (2014). Julien’s primer of drug action: A comprehensive guide to the actions, uses, and side effects of psychoactive drugs (13th ed.). New York, NY: Worth Publishers. 
McLean, W., (2018). A Critical review of the efficacy and safety of saffron. Journal of the Australian Traditional Medicine Society. Retrieved from http://eds.a.ebscohost.com.proxy-library.ashford.edu/eds/pdfviewer/pdfviewer?vid=0&sid=045e4a13-d3ef-4f6c-93b8-4a652cb445e2%40sessionmgr4006 (Links to an external site.)Links to an external site. 
Tackman, A. & Sbarra, D. & Carey, A. & Donnellan, B. & Horn, A. & Holtzman, N. & Edwards, T. & Pennebaker, J. & Mehl, M. (2018). Depression, negative emotionality, and self-referential language-task research synthesis. Journal of Personality and Social Psychology. Doi: pspp0000187. Retrieved from http://eds.a.ebscohost.com.proxy-library.ashford.edu/eds/pdfviewer/pdfviewer?vid=0&sid=33969e9c-8698-466b-86cd-d10f6c7a3670%40sessionmgr4009 (Links to an external site.)Links to an external site. 
Mennin, D. & Fresco, D. & O’Toole, M. & Heimberg, R. (2018). A Randomized controlled trial of emotion regulation therapy for generalized anxiety disorder with and without co-occurring depression. Journal of Consulting and Clinical Psychology. Doi: 10.1037/ccp0000289 Retrieved from http://eds.a.ebscohost.com.proxy-library.ashford.edu/eds/pdfviewer/pdfviewer?vid=0&sid=80bd0144-0537-4bae-9f98-59c58bdd4f82%40sessionmgr4006  

Reply